2024
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, 230: 1093-1101. PMID: 38536442, PMCID: PMC11565884, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults
2020
The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
McAteer J, Yildirim I, Chahroudi A. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. Clinical Infectious Diseases 2020, 71: 703-705. PMID: 32282038, PMCID: PMC7184475, DOI: 10.1093/cid/ciaa433.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Vaccines actCoronavirus 2Clinical trialsVaccine hesitancyVaccine candidatesNovel vaccinesCOVID-19COVID-19 pandemicVaccineTimes of COVID19PandemicTrials